• Ciclesonide: An Assay-First Mechanistic Guide

  2026-09-21

  Ciclesonide research depends on separating prodrug activation, glucocorticoid receptor binding, and downstream anti-inflammatory effects. This assay-first guide also clarifies what the 2026 ERAD study does—and does not—demonstrate about desisobutyryl-ciclesonide and targeted protein degradation.

• (+)-Bicuculline: Practical GABAA Workflow

  2026-09-21

  This guide explains how to use (+)-Bicuculline as a GABAA receptor antagonist for controlled studies of inhibitory neurotransmission, synaptic NMDA receptor signaling modulation, and related neuronal endpoints. It is intended for research workflows only, not diagnostic or medical use, and emphasizes solvent selection, storage, controls, and interpretation limits.

• Patient-Derived Gastric Cancer Assembloids

  2026-09-19

  Shapira-Netanelov and colleagues developed patient-derived gastric cancer assembloids that combine matched tumor organoids with stromal subpopulations from the same tumor. The model reproduced clinically relevant tumor–stroma interactions and revealed that stromal composition can change gene expression and drug sensitivity, supporting more informative personalized preclinical testing.

• Cinoxacin Workflows for Gram-Negative Research

  2026-09-18

  Cinoxacin provides a practical quinolone antibiotic framework for susceptibility testing, urinary tract infection research, and resistance modeling in selected Gram-negative organisms. This guide combines product-specific handling guidance with endpoint and control lessons adapted cautiously from a modern clinical trial design.

• Annexin V-PE Apoptosis Detection Kit Guide

  2026-09-18

  Learn how the Annexin V-PE Apoptosis Detection Kit converts phosphatidylserine exposure into a decision-ready apoptosis readout. This guide connects live-cell assay design with the GANT61–Hh–PIK3IP1–Akt findings in ALK-positive lymphoma while clarifying interpretation limits.

• Exogenous NADH Potentiates Aminoglycosides in E. tarda

  2026-09-17

  A 2024 Virulence study shows that exogenous NADH can reprogram Edwardsiella tarda metabolism, increase ATP availability, and strengthen the bactericidal activity of neomycin and other antibiotic classes. The work presents metabolic stimulation as an antibiotic-adjuvant strategy, while emphasizing the need for strain-specific, safety, and in vivo validation.

• Lypressin Acetate: From Receptor Signal to Assay

  2026-09-17

  Lypressin acetate is a lysine-substituted vasopressin analog with coordinated V1a, V1b, and V2 receptor activity. This guide goes beyond product description to show how receptor biology, functional controls, and evidence maturity should shape assay design.

• From CA2 PNN Loss to Translational Assays

  2026-09-16

  A mechanistic and translational framework for connecting hippocampal perineuronal-net biology with exploratory cGMP measurement using 8-DY547-cGMP.

• Measuring Drug Response Beyond Cell Viability

  2026-09-16

  Hannah R. Schwartz’s dissertation shows that relative viability and fractional viability capture different components of an in vitro cancer-drug response: growth inhibition and cell killing. Its central implication is practical: drug evaluation should separate response magnitude from response type and should account for timing before drawing mechanistic or translational conclusions.

• Vasopressin Analogues: Mechanisms, Methods, and Uses

  2026-09-15

  The reference review explains how structural changes to vasopressin generate distinct receptor selectivity, duration, and therapeutic profiles. Its comparison of lypressin, desmopressin, terlipressin, and related analogues provides a framework for interpreting antidiuretic, vasoconstrictor, and emerging antiviral research.

• RIPA Lysis Buffer Strong: Practical Protocol

  2026-09-15

  RIPA Lysis Buffer (Strong, without inhibitors) provides detergent-based extraction for animal cells and tissues when robust protein solubilization is needed. It is appropriate for workflows such as Western blotting and screening assays, but its strong detergent composition requires validation for native immunoprecipitation complexes and enzyme activity measurements.

• PLGA Microspheres for Controlled Cartilage Corticosteroids

  2026-09-14

  The 2026 Pharmaceutics study shows that PLGA microsphere size, surface chemistry, and drug stability jointly determine corticosteroid transport through articular cartilage. Its combination of emulsion fabrication, bovine explant diffusion testing, HPLC, and hydrolysis analysis provides a practical framework for designing more predictable intra-articular delivery systems.

• Cyclic di-GMP: From Biofilm Signal to STING

  2026-09-14

  Cyclic di-GMP is an intracellular second messenger with distinct bacterial and mammalian experimental roles. This article explains how to separate biofilm-persistence mechanisms from STING-driven immune modulation when designing rigorous, cross-domain assays.

• ATRX Loss Sensitizes High-Grade Glioma to RTK Inhibitors

  2026-09-13

  The reference study identifies ATRX deficiency as a context associated with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its drug-screening and temozolomide-combination data support ATRX status as a candidate biomarker for interpreting targeted-therapy responses, although clinical validation remains necessary.

• AZD1480: From JAK2 Potency to Cancer Insight

  2026-09-12

  AZD1480 is a potent JAK2 inhibitor for connecting biochemical target engagement with STAT3-dependent tumor phenotypes. This guide presents a decision-oriented workflow for interpreting pathway inhibition, combination studies, and model-specific responses.

8101 records 1/541 page Next 12345 下5页 Last page